News - Celladon Corporation
Research conducted by University of Minnesota scientists, in collaboration with Celladon Corporation, has led to the invention of technology to more rapidly identify compounds for the treatment of heart failure.
Phase 1 Data Demonstrate Safety and Evidence of Biological Activity in 9 of 12 Patients; Phase 2 Study Currently Enrolling in 17 Leading U.S.
Phase 1/2 Calcium Upregulation by Percutaneous Administration (CUPID) Data Highlight Safety Profile and Biological Effects of SERCA2a Enzyme Replacement SAN DIEGO, May 26 /PRNewswire/ -- Celladon Corporation today announced that results from its genetically targeted enzyme replacement therapy for advanced heart failure, including Phase 1/2 data of MYDICAR(R) (AAV1/SERCA2a), will be presented by Krisztina M.
Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial) Demonstrated Safety and Biological Effects of SERCA2a Enzyme Replacement Using Gene Transfer SAN DIEGO, April 8 /PRNewswire/ -- Celladon Corporation today announced the publication of results from a Phase 1/2 trial of MYDICAR(R) (AAV1/SERCA2a), a genetically targeted enzyme replacement therapy for advanced heart failure, in the April 2009 issue of the Journal of Cardiac Failure.